TIDMPRTC
RNS Number : 6383S
PureTech Health PLC
18 March 2021
18 March 2021
PureTech Health plc
PureTech Announces Board Member Retirement
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, today announces that Stephen
Muniz, Esq., will retire from his role as Chief Operating Officer
and Corporate Secretary and will step down from the Board Of
Directors, effective May 17, 2021. Bharatt Chowrira, PhD, JD,
PureTech's President and Chief of Business and Strategy and a
member of the Board, will assume the responsibilities previously
held by Steve.
"On behalf of the Board, I would like to thank Steve for all of
his hard work and leadership over the past 13 years," said Daphne
Zohar, Founder and Chief Executive Officer of PureTech. "As a
co-founder, Steve has been instrumental in helping PureTech build a
world class operations and legal team, leaving us well-positioned
for the future. We wish him much continued success and all the best
in his future endeavors ."
"It has been an honor to help build such an innovative company,"
said Steve. " I am looking forward to watching PureTech's progress
as they continue to advance their important therapeutic candidates
and ground-breaking discovery platforms for patients in need ."
PureTech's Board of Directors
PureTech's Board of Directors include former executives of major
pharmaceutical companies, entrepreneurs, and award winning academic
and clinical leaders who leverage their expertise to support our
mission. The Board of Directors is comprised of the following
members:
Daphne Zohar, Founder, Chief Executive Officer and Director -
Daphne Zohar is the Founder and Chief Executive Officer of
PureTech, and she has served as a member of PureTech's Board of
Directors since the Company's founding. She has also served as the
founding Chief Executive Officer of a number of PureTech's Founded
Entities. A successful entrepreneur, Ms. Zohar created PureTech,
assembling a leading team to help implement her vision for the
Company, and was a key participant in fundraising, business
development and establishing the underlying programs and platforms
that have resulted in PureTech's substantial pipeline.
Chris Viehbacher, Board Chair - Chris Viehbacher has served as a
member of PureTech's Board of Directors since 2015 and as Chair
since September 2019. He is the Managing Partner of Gurnet Point
Capital, a Boston based investment fund associated with the
Bertarelli family and has a $2 billion capital allocation. He is
the former CEO and member of the Board of Directors of Sanofi and
was also the Chair of the Board of Genzyme in Boston.
Bharatt Chowrira, PhD, JD, President, Chief of Business and
Strategy and Director - Bharatt Chowrira, PhD, JD, is the President
and Chief of Business and Strategy of PureTech, and he has served
as a member of PureTech's Board of Director's since 2021. Prior to
joining PureTech, Dr. Chowrira was the President of Synlogic, Inc.
He previously served as the Chief Operating Officer of Auspex
Pharmaceuticals Inc., until its acquisition by Teva
Pharmaceuticals, and he has held various leadership and management
positions across the biopharmaceutical industry.
Raju Kucherlapati, PhD, Independent Non-Executive Director -
Raju Kucherlapati, PhD, has served as a member of PureTech's Board
of Directors since 2014. He is the Paul C. Cabot Professor of
Genetics and Professor of Medicine at Harvard Medical School. Dr.
Kucherlapati was a founder and formerly a board member of Abgenix
(acquired by Amgen for $2.2 billion), Cell Genesys and Millennium
Pharmaceuticals (acquired by Takeda for $8.8 billion).
John LaMattina, PhD, Independent Non-Executive Director - John
LaMattina, PhD, has served as a member of PureTech's Board of
Directors since 2009. Dr. LaMattina was previously president of
Pfizer Global Research and Development and held positions of
increasing responsibility during his 30-year career at Pfizer.
Bob Langer, ScD, Co-Founder and Non-Executive Director - Bob
Langer, ScD, is a Co-founder of PureTech and has served as a member
of PureTech's Board of Directors since the Company's founding. He
has served as the David H. Koch Institute Professor at MIT since
2005. He is one of 12 institute professors, which is the highest
honor that can be awarded to a faculty member at MIT. Dr. Langer
has received over 220 major awards and is the most cited engineer
in history.
Kiran Mazumdar-Shaw, Independent Non-Executive Director - Kiran
Mazumdar-Shaw has served as a member of PureTech's Board of
Directors since 2020. She is a pioneering biotech entrepreneur, a
healthcare visionary, a global influencer and a passionate
philanthropist. She is a pioneer of India's biotech industry and
founder of Biocon.
Dame Marjorie Scardino, Senior Independent Director - Dame
Marjorie Scardino has served as a member of PureTech's Board of
Directors since 2015. She served as Chief Executive of The
Economist for 12 years and was the Chief Executive of Pearson plc,
the world's leading education company and the owner of Penguin
Books and The Financial Times Group. She served as chairman of The
MacArthur Foundation from 2012 to 2017, and later became the
Chairman of the London School of Hygiene and Tropical Medicine.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
as of the date of PureTech's most recently filed Registration
Statement on Form 20-F, was comprised of 24 therapeutics and
therapeutic candidates, including two that have received FDA
clearance and European marketing authorization. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our therapeutic candidates and those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
Contact:
Investors EU media U.S. media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADZGMFMNDGMZZ
(END) Dow Jones Newswires
March 18, 2021 03:00 ET (07:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Nov 2023 to Nov 2024
